ImaBiotech group is a global one-stop-shop bioanalytical contract research organization (CRO) combining the capabilities of ImaBiotech (Lille, France) and Pyxant Labs (Colorado Springs, USA).

ImaBiotech, with facilities in Boston (USA) and Lille (France), combines innovative mass spectrometry imaging and proprietary spatial biology techniques to decipher the complexity of drug activity. The combination of unique capabilities with advanced digital pathology tools enables the measurement of drug activity and drug response, simultaneously, at the single cell level. ImaBiotech’s services cover the drug efficacy evaluation from preclinical to clinical stages.

Pyxant Labs, with sites in Colorado Springs and Salt Lake City in North America, provides innovative bioanalytical solutions for advancing leading-edge and challenging drug development programs to support early-stage drug discovery, pre-clinical studies and clinical trial sample analysis. Utilizing high resolution mass spectrometry and traditional mass spectrometry, Pyxant Labs is recognized for its fast-turnaround drug discovery services, leading science and regulatory leadership.

The integration of the expertise, innovation and analytical platforms of ImaBiotech and Pyxant Labs to form a leading global bioanalytical services provider, provides a unique offering to the pharmaceutical and cosmetic industry, revealing the true picture of the efficacy of a drug or the relevance of a biomarker throughout all stages of drug research.

  • Investment date

    2021

  • Sector

    Biopharma Services

  • Transaction type

    Buy-Out

  • Growth theme

    Innovation / Internationalization / Buy & Build

  • Location

    France / United States